CGC
NYSECanopy Growth Corporation
SectorHealth CareIndustry Medicinal Chemicals and Botanical Products
Price$1.04-0.05 (-4.59%)
2026-03-042026-06-05
News · 26 weeks37-40%
2025-12-142026-06-07
Mix1890d
- Other7(39%)
- Insider4(22%)
- Leadership3(17%)
- SEC Filings3(17%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form SD filed by Canopy Growth CorporationSD - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following AcquisitionPablo's Revenge, Dante'z Inferno, and Frost'd Flakes launched under Tweed brand Up to five additional strains expected to follow in June 2026 Company targeting rapid growth in Germany's medical cannabis market Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. ("MTL"), a wholly-owned subsidiary of the Company. The dual milestone represents the Company's first international product release following its recent acquisition of MTL. This press release features multimedia. View the full release
- SECCanopy Growth Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Canopy Growth Corp (0001737927) (Filer)
- SECCanopy Growth Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the "Refiling"), in conjunction with its filing of financial results for the year ended March 31, 2026 on June 15, 2026, as further described below and in the Company's material change report and the Company's Current Report on Form 8-K each dated May 15, 2026. During the Company's year-end
- PREurope's Cannabis Boom Is Accelerating as Billions Flow into Licensed MarketsNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Europe's licensed cannabis industry is starting to look like one of the most exciting growth stories in the global cannabis market. What was once a fragmented, slow-moving sector is now gaining serious momentum as more countries open up medical cannabis programs, expand patient access, and create clearer licensing frameworks for producers and distributors. Germany continues to lead the charge after its cannabis reforms, but countries like the UK, Portugal, Italy, France, Switzerland, and the Czech Republic are also becoming major pieces of the puzzle. Investors and operators are paying close attention because
- PRCanopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing OptionsInformed innovation delivers same trusted quality with improved value, flexible dosing, and better alignment with patient needs Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and Spectrum Therapeutics today announced an expansion of its Minor Cannabinoid softgel lineup, introducing new 30 and 90-pack formats and additional dosing options across its Optimized Spectrum portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507336358/en/Clarity, Unwind, and Daily Relief 90-pack softgel formats are available now to patients through Spectrum Therapeutics The expansion builds on the strong
- PR'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer CampaignNew window bags, improved potency, and sharper pricing arrive at retail Victoria Day long weekend Canopy Growth Corporation ("Canopy Growth", "Canopy" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, "There's a Tweed for That." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423388138/en/The Tweed summer campaign launches over the Victoria Day long weekend, the traditional kickoff to the Canadian summer, spotlighting Tweed's updated portfolio, including three new flower strains and the popular Quickies pre-ro
- INSIDERSEC Form 4 filed by Yanofsky Theresa4 - Canopy Growth Corp (0001737927) (Issuer)
- INSIDERSEC Form 4 filed by Atkins M Shan4 - Canopy Growth Corp (0001737927) (Issuer)
- INSIDERSEC Form 4 filed by Bayern Joseph4 - Canopy Growth Corp (0001737927) (Issuer)
- INSIDERSEC Form 4 filed by Lazzarato David Angelo4 - Canopy Growth Corp (0001737927) (Issuer)
- PRCanopy Growth Unveils New Brand 'Deelish': High THC, Everyday Price27%-33% THC flower, and 26%-32% THC pre-rolls across rotating genetics Now available at select stores across Ontario and Alberta Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced Deelish ("DEE-LISH"), a new cannabis brand built for the everyday consumer with an everyday price. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331523789/en/High THC, Everyday Price. Deelish is Canopy Growth's newest brand, delivering high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. Deelish enters the market built to deliver high THC with flower testing at 27%-33% THC a
- PRCanopy Growth's Apollo Cannabis Clinics Named Best Medical Cannabis ClinicVoted best by Toronto Star Readers' Choice Awards Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced that its Apollo Cannabis Clinics ("Apollo") has been named Best Medical Cannabis Clinic in the 2025 Toronto Star's Readers' Choice Awards, a public vote that reflects the trust patients place in Apollo's care. Apollo represents the Company's commitment to raising the standard of medical cannabis and making quality treatment accessible to every Canadian. "This recognition comes directly from the people we care for, and that makes it especially meaningful," said Luc Mongeau, Chief Executive Officer of Canopy Growth. "Everything Apollo doe
- ANALYSTCanaccord Genuity initiated coverage on Canopy GrowthCanaccord Genuity initiated coverage of Canopy Growth with a rating of Buy
- PRCanopy Growth Announces Storz & Bickel Executive TransitionDavid Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p
- SECCanopy Growth Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Canopy Growth Corp (0001737927) (Filer)
- PRCanopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By RevenueThis news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab
- PRCanopy Growth Announces MTL Cannabis Shareholder Approval of AcquisitionCanopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce that shareholders of MTL Cannabis Corp. ("MTL Cannabis" or "MTL") have voted to approve the Company's previously announced acquisition of MTL (the "Transaction") at a special meeting of shareholders of MTL (the "MTL Shareholders") held February 17, 2026. The plan of arrangement with Canopy Growth received overwhelming support from MTL Shareholders, with (i) 99.97% of all shares of MTL (the "MTL Shares") cast in favour of the special resolution approving the Transaction, and (ii) 99.80% of MTL Shares, excluding votes attached to MTL Shares required to be excluded pursuant to Multilat
- SECSEC Form EFFECT filed by Canopy Growth CorporationEFFECT - Canopy Growth Corp (0001737927) (Filer)
- SECSEC Form 424B3 filed by Canopy Growth Corporation424B3 - Canopy Growth Corp (0001737927) (Filer)
- INSIDERChief Executive Officer Mongeau Luc sold $9,951 worth of shares (9,376 units at $1.06), decreasing direct ownership by 1% to 802,992 units (SEC Form 4)4 - Canopy Growth Corp (0001737927) (Issuer)
- SECSEC Form S-3 filed by Canopy Growth CorporationS-3 - Canopy Growth Corp (0001737927) (Filer)
- SECCanopy Growth Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Canopy Growth Corp (0001737927) (Filer)
- SECSEC Form 10-Q filed by Canopy Growth Corporation10-Q - Canopy Growth Corp (0001737927) (Filer)
CGC FAQ
6 questionsWhat does Canopy Growth Corporation do?
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop...Where does CGC stock trade?
Canopy Growth Corporation (CGC) is listed on NYSE.What sector and industry is CGC in?
Canopy Growth Corporation operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about CGC?
Canopy Growth Corporation has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-03-27.What companies are similar to CGC?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare CGC side-by-side with any of them on Quantisnow.How can I track CGC on Quantisnow?
Quantisnow aggregates Canopy Growth Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGC to receive live email and push alerts on every new disclosure.